Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
13 Results for "
A2058 cells
" in MedChemExpress (MCE) Product Catalog:
Products (13)
13 Results for "A2058 cells" in MCE Product Catalog:
13
13 Publications Verification
13
13 Publications Verification
Cat. No.: HY-123071A
Purity: 99.24%
7
7 Cited Publications
Cat. No.: HY-16462
CAS No.: 1263369-28-3
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.
Category:
Rutaceae Coumarins Phenylpropanoids Plants Disease Research Fields Cancer Citrus medica Linn. var. sarcodactylis (Noot.) Swingle
Target:
Synonyms: 5,7-Dimethoxycoumarin (Standard); Limettin (Standard)
Category:
Rutaceae Coumarins Phenylpropanoids Plants Citrus medica Linn. var. sarcodactylis (Noot.) Swingle
Target:
Cat. No.: HY-16461
CAS No.: 137038-57-4
Synonyms: (-)-Solenopsin A
Category:
Cat. No.: HY-174837
Target:
Research Areas:
Topoisomerase IIα-IN-11 (Compound 16h) is a potent Topoisomerase IIα inhibitor. Topoisomerase IIα-IN-11 shows significant inhibition on melanoma A2058 cell lines (IC50 3-6 μM). Topoisomerase IIα-IN-11 is promising for research of cancers (especially melanoma) .
Cat. No.: HY-150061
CAS No.: 853910-61-9
NVP-BBD130 is a potent, stable, ATP-competitive and orally active dual PI3K and mTOR inhibitor . NVP-BBD130 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-N16691
CAS No.: 24177-16-0
Target:
Cat. No.: HY-181602
Target:
Research Areas:
ATP Synthesis-IN-4 is a mitochondria-targeted small-molecule ligand that inhibits ATP synthesis. ATP Synthesis-IN-4 binds to mtDNA G4s in melanoma cells, thereby inducing changes in mitochondrial metabolism and inhibiting cell proliferation. ATP Synthesis-IN-4 suppresses the translation of key mitochondrial respiratory chain proteins (CYTB, ATP8, COX1, COX3, ND2) in melanoma cells, downregulates the expression of OXPHOS complexes, activates the phosphorylation of AMPK, and induces metabolic reprogramming to upregulate glycolysis. ATP Synthesis-IN-4 is applicable to relevant research on melanoma .
Cat. No.: HY-182275
Target:
Research Areas:
PROTAC PRMT1 degrader-1 (compound 4) is a PRMT1 PROTAC degrader, with a DC50 of 0.77 μM (MCF-7 cells). PROTAC PRMT1 degrader-1 recruits the CRBN E3 ubiquitin ligase to induce proteasome-dependent degradation of PRMT1; it also forms a ternary complex with PRMT1 and CRBN, promoting ubiquitination and subsequent proteasomal degradation of PRMT1. PROTAC PRMT1 degrader-1 reduces the level of asymmetric dimethylarginine in cancer cells, as well as the level of asymmetric dimethylation of arginine 3 on histone H4, while inhibiting the growth of various cancer cells. PROTAC PRMT1 degrader-1 can be used in the research of breast cancer and melanoma .
Cat. No.: HY-119601
CAS No.: 313685-55-1
Target:
Research Areas:
GRI918013 (compound 1) is a selective and competitive autotaxin (ATX/NPP2) inhibitor with anti-invasive and anti-metastatic activity. GRI918013 competitively binds to ATX, blocking lipid substrates such as lysophosphatidylcholine (LPC) from entering the ATX active site, thereby inhibiting ATX-mediated hydrolysis of LPC to lysophosphatidic acid (LPA), and consequently inhibiting ATX-LPA axis-related tumor cell invasion and metastasis. GRI918013 inhibits ATX-mediated hydrolysis of the LPL substrate FS-3 (IC50=31.42 nM, Ki=12.98 nM). GRI918013 can be used in research on cancer invasion and metastasis, such as melanoma, and can also serve as a tool compound for ATX-LPA axis-related diseases such as fibrotic diseases, neuropathic pain, and cholestatic pruritus .
Cat. No.: HY-183400
CAS No.: 195450-11-4
Target:
Neurotensin Receptor MMP EGFR Toll-like Receptor (TLR) Wnt Caspase PARP MyD88 NF-κB TNF Receptor Apoptosis
Research Areas:
BIM-46174 is a heterotrimeric G protein complex inhibitor. BIM-46174 blocks GPCR downstream signaling by trapping Gα proteins in a nucleotide-free pocket conformation, thereby inhibiting Gαq-mediated calcium release, Gαs-mediated cAMP production, and GPCR-regulated cancer cell invasion. In vitro, BIM-46174 effectively suppresses a variety of clinically multidrug-resistant cell lines and induces tumor cell apoptosis through activation of caspase-3 and PARP cleavage. BIM-46174 also inhibits activation of the Neu1-MMP-9-GPCR signaling platform and downstream NF-κB signaling, and is widely used in the study of cancer signaling pathways and inflammation-related research, including lung cancer, pancreatic cancer, breast cancer, melanoma, and leukemia .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
